The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3
The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2
This follows the recent U.S. FDA approval for Restylane Lyft for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wakeupready’ beauty4

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3

With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.3,8,9 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years resulting in a growing area of aesthetic need.3,8,9 Galderma is spearheading efforts to address these concerns, including with this latest approval for Restylane Contour, which provides a new option for increasing volume in the temples to help restore balance for a more refreshed, youthful look.1-3 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Contour enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals.1-3 Restylane Contour is powered by OBT™/XpresHAn™ technology, which integrates into the skin and balances support and flexibility, to provide long-lasting, natural-looking results that move with facial expressions.1-3,6